Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Marianne De Backer
AddedFeb 19, 2024
UpdatedMay 31, 2026
Marianne De Backer

Marianne De Backer

Board Member, Arrowhead Pharmaceuticals

CrunchbaseLinkedInThe Org

Marianne De Backer's Career

Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals

Pasadena, CA, US

Board Member· Board
Kronos Bio
Kronos Bio

San Mateo, CA, US

Board Member· Board
Vir Biotechnology
Vir Biotechnology

San Francisco, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Marianne De Backer's Career

Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals
NonprofitNonprofit$899.9M5252001Pasadena, CA, US
Board Member· Board

Leadership at Arrowhead Pharmaceuticals

William D. WaddillWilliam D. WaddillBoard Member
Vicki VakienerVicki VakienerBoard Member
Oye OlukotunOye OlukotunBoard Member
Doug GivenDoug GivenBoard Member
Mauro FerrariMauro FerrariBoard Member
Christopher AnzaloneChristopher AnzaloneCEO
Kronos Bio
Kronos Bio

San Mateo, CA, US

Board Member· Board
Vir Biotechnology
Vir Biotechnology
Public$908.6M5762016San Francisco, CA, US
CEO· C-Suite · Management

Leadership at Vir Biotechnology

Phillip A. SharpPhillip A. SharpBoard Member
Elliott SigalElliott SigalBoard Member
Rob PerezRob PerezBoard Member
Louis PickerLouis PickerCo-Founder
Klaus FruehKlaus FruehCo-Founder
Vicki SatoVicki SatoBoard Member

Similar to Vir Biotechnology

Virion TherapeuticsVirion TherapeuticsNewark, DE, USImmunotherapy, Vaccinesest. 2018Virion TherapeuticsNewark, DE, US · est. 2018

Virion Therapeutics: A global biotech firm innovating vaccines for cancers and chronic viral infections.

Series B · $14.1M8
ViriomViriomSan Diego, CA, USHBV Treatments, HIV Treatmentsest. 2009ViriomSan Diego, CA, US · est. 2009

Viriom: A therapeutic biotech firm innovating treatments for HIV and Hepatitis B.

Series B · $35.4M200
Precision VirologicsPrecision VirologicsSt. Louis, MO, USBiotechest. 2016Precision VirologicsSt. Louis, MO, US · est. 2016

Precision Virologics: A St. Louis-based biotech startup innovating in virology.

Angel · $1M6
TherabiolTherabiolSan Francisco, CA, USImmune Therapiesest. 2012TherabiolSan Francisco, CA, US · est. 2012

Therabiol, Inc.: A San Francisco-based biotech firm specializing in developing immune therapies for viral infections.

Seed · $150k5

Marianne De Backer's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWillix HalimWillix HalimCEO · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailHiroshi MikitaniHiroshi MikitaniBoard Member · RakutenMickey MikitaniMickey MikitaniCEO · Rakuten

People Similar to Marianne De Backer

Dallas HackDallas HackCEO · VirTech BioIain DukesIain DukesBoard Member · ImageneBioChris ViehbacherChris ViehbacherBoard Member · Before BrandsMatías VidalMatías VidalFounder · VirTech Bio